Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven).
Tanaka
Kenichi A
KA
Department of Anesthesiology, Emory University School of Medicine and Division of Cardiothoracic Anesthesiology and Critical Care, Emory Healthcare, Atlanta, Georgia 30322, USA.
Waly
Amr A
AA
Cooper
William A
WA
Levy
Jerrold H
JH
D000368:Aged; D016063:Blood Loss, Surgical; D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006679:HIV Seropositivity; D019918:Heart Valve Prosthesis Implantation; D006470:Hemorrhage / Q000188:drug therapy*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D007431:Intraoperative Complications / Q000188:drug therapy*; D033221:Jehovah's Witnesses; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery; D019106:Postoperative Hemorrhage / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use
D006490:Hemostatics; D011994:Recombinant Proteins; D015942:Factor VIIa